Comparing the current results to its competitors, Centessa Pharmaceuticals Plc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.31 %, recorded in the same quarter.
Centessa Pharmaceuticals Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 76.57 %
Centessa Pharmaceuticals Plc's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic research institutions, governmental agencies, and other public and private research organizations worldwide. Notable competitors developing programs for orexin indications include Takeda Pharmaceuticals Company Limited and Alkermes plc. These competitors may possess greater financial resources and expertise in areas such as research, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies can also present significant competition, particularly through collaborations. Competition extends to recruiting qualified personnel, establishing clinical trial sites, enrolling patients, acquiring complementary technologies, and securing strategic partnerships, licensing, or acquisition opportunities. The negotiation process for partnerships is complex and time-consuming, potentially affecting the company's ability to develop its product pipeline. Additionally, patent protection and priority of inventions remain uncertain due to confidentiality and possible interference proceedings by the United States Patent and Trademark Office.
September 26, 2024
In an exciting revelation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024), Centessa Pharmaceuticals unveiled compelling preclinical data for ORX142, a novel Orexin Receptor 2 (OX2R) agonist. This groundbreaking late-breaking poster presentation shines a light on the potential of ORX142 as a transformative treatment for excessive daytime sleepiness (EDS) linked to various neurological, neurodegenerative, and psychiatric disorders. The Growing Problem of Excessive Daytime SleepinessExcessive daytime sleepiness is a prevalent issue, significantly impacting the quality of life for individuals battling conditions such as narcolepsy, Alzheimer’s disease, Parkinson’s disease, and...
April 22, 2024
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, recently received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 first-in-human, clinical trial of ORX750. This investigational drug shows potential efficacy in addressing the underlying pathophysiology of narcolepsy, specifically type 1 (NT1), with potential applications in narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other sleep-wake disorders. This article aims to present the facts surrounding ORX750 and its potential impact on patients suffering from narcolepsy.Key Facts:1. ORX750 is an orally administered, highly potent, and selective orexin receptor 2 (OX2R) agonist. By directly target...
March 28, 2024
The biopharmaceutical industry continues to be a locus of innovation and progress, with companies reporting encouraging positive strides which directly impact global healthcare. A pivotal actor in this sector is Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical organization. Recently, the company reported its business highlights and financial results for Q4 and the full-year ending December 31, 2023. The announcement encompassed data from both its Boston and London locations.Centessa Pharmaceuticals strives to bring decisive innovation into an industrial model by selectively combining the rigor of biopharmaceutical development with the entrepreneurial spirit and agility associated ...
Publicly Traded Peers of Centessa Pharmaceuticals Plc
Inflarx N V Share Performance
+25.62%
This Quarter
Inflarx N V
Profile
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Sources:
Centessa Pharmaceuticals Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Centessa Pharmaceuticals Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
